Skip to main content


Study of the efficacy and safety of various anti-inflammatory agents in participants with mild cognitive impairment or mild Alzheimer's disease

Novartis Pharmaceuticals
Clinical Trial

Information about the drug that will be tested in the study

Name of the drug

Several anti-inflammatory agents will be tested. The first anti-inflammatory treatment used in this study is called Canakinumab (also named ACZ885).


Canakinumab will be administered via a subcutaneous injection (an injection under the skin).

Is the drug already on the market for another medical condition?

Yes - Arthritis

Will all participants receive the same drug?

Participants will be selected at random to either receive one of the following options:

  • A subcutaneous injection of Canakinumab
  • A subcutaneous injection of placebo (also called a dummy treatment which is an inactive substance identical in appearance to the drug being tested with no active therapeutic effect).

Neither the participant nor his/her doctor will know if the person is receiving the investigational drug or the placebo.

Information about participating in the trial

What are the researchers trying to find out?

The purpose of the study is to evaluate the safety, tolerability and efficacy of anti-inflammatory agents in people with mild cognitive impairment or mild Alzheimer's disease with evidence of peripheral inflammation.

How long will the treatment last?
  • A treatment period of 20 weeks (around 5 months)
  • After the 20-week period, study participant will be eligible to enter a follow-up period of 28 days.
What your involvement will entail?
  • During the study, participants will be asked to complete a test that will assess their cognitive domain, in particular memory, executive function, attention and verbal fluency (this is a test called NTB)
  • To complete some laboratory/biological tests (i.e. blood tests, ECG) to evaluate the emergent adverse effects (unfavourable signs, symptoms or diseases temporally associated with the use of the drug tested in the study)
  • To complete other tests that will assess their neuropsychiatric symptoms, activities of daily living and memory (i.e. tests like NPI, eCog, MMSE)
  • Participants will be asked to undertake brain scans (PET) to see changes in biomarkers in the brain.

Further information on the procedures, tests and number of visits can be obtained from the study team.

Who can participate in this study?

Who can participate in the study?

To take part in the study, participants must:

  • Be between 45 and 90 years old
  • Have a diagnosis of probable mild cognitive impairment due to Alzheimer's disease or a diagnosis of mild Alzheimer's disease according to the National Institute on Aging/Alzheimer's Association core clinical criteria
  • Have a score of between 20 and 30 in the MMSE test questionnaire test (a test about your memory). This would suggest that the person has an impairment in their memory that is at a mild stage
  • Have evidence of abnormal accumulation of amyloid and tau in the brain, determined through CSF examination (lumbar puncture)
  • Have a study partner who has a sufficient contact with the participant, is willing to participate in study procedures throughout the study duration.
Who cannot participate in the study?

People cannot take part in the study if they have or have experienced:

  • A disease or conditions that may interfere with the safety, tolerability and/or study assessments (e.g., non-Alzheimer dementia, Huntington's disease, Parkinson's disease, stroke, schizophrenia, bipolar disorder, active major depression, multiple sclerosis)
  • Diagnosis of vascular dementia prior to screening
  • Previous treatment with amyloid vaccines or intravenous immunoglobulins meant to treat Alzheimer's disease.

The above list is not exhaustive. It includes the most common conditions and diseases that might exclude people from the study.

Information for your doctor

EudraCT Number

2020-003966-38 identifier


Study contact information

Link to full text

The information contained in this document is based on information available on public registries (e.g. website) on March 2022.


Alzheimer Europe's Clinical Trials Watch database was developed as part of the 2018 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).

Alzheimer Europe gratefully acknowledges the support of its corporate sponsors for the update and maintenance of the database.